New aspects of diagnosis and therapy of hepatocellular carcinoma

被引:128
作者
Bruix, J
Hessheimer, AJ
Forner, A
Boix, L
Vilana, R
Llovet, JM
机构
[1] Univ Barcelona, BCLC Grp, Liver Unit, IDIBAPS,Digest Dis Inst,Hosp Clin, E-08036 Barcelona, Catalonia, Spain
[2] Univ Barcelona, BCLC Grp, Dept Radiol, IDIBAPS,Hosp Clin, E-08036 Barcelona, Catalonia, Spain
关键词
hepatocellular carcinoma; early detection; diagnosis; treatment;
D O I
10.1038/sj.onc.1209548
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocellular carcinoma is one of the major cancer killers. It affects patients with chronic liver disease who have established cirrhosis, and currently is the most frequent cause of death in these patients. The main risk factors for its development are hepatitis B and C virus infection, alcoholism and aflatoxin intake. If acquistion of risk factors is not prevented and cirrhosis is established, the sole option to improve survival is to detect the tumor at an early stage when effective therapy may be indicated. Early detection plans should be based on hepatic ultrasonography every 6 months, whereas determination of tumor markers is not efficient. Upon detection of a hepatic nodule, there is a need to establish unequivocal diagnosis, either through biopsy or through the application of non-invasive criteria based on the specific radiology appearance of the tumor: fast arterial uptake of contrast followed by venous washout. Effective treatment for liver cancer includes surgical resection, liver transplantation and percutaneous ablation. These options provide a high rate of complete responses and are assumed to improve survival that should exceed 50% at 5 years. If the tumor is diagnosed at an advanced stage, the sole option that improves survival is transarterial chemoembolization. Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression.
引用
收藏
页码:3848 / 3856
页数:9
相关论文
共 76 条
  • [21] Risk factors contributing to early and date phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
    Imamura, H
    Matsuyama, Y
    Tanaka, E
    Ohkubo, T
    Hasegawa, K
    Miyagawa, S
    Sugawara, Y
    Minagawa, M
    Takayama, T
    Kawasaki, S
    Makuuchi, M
    [J]. JOURNAL OF HEPATOLOGY, 2003, 38 (02) : 200 - 207
  • [22] Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity
    Ishizuka, H
    Nakayama, T
    Matsuoka, S
    Gotoh, I
    Ogawa, M
    Suzuki, K
    Tanaka, N
    Tsubaki, K
    Ohkubo, H
    Arakawa, Y
    Okano, T
    [J]. INTERNAL MEDICINE, 1999, 38 (12) : 927 - 931
  • [23] IZUNO K, 1995, HEPATO-GASTROENTEROL, V42, P387
  • [24] Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
    Jonas, S
    Bechstein, WO
    Steinmüller, T
    Herrmann, M
    Radke, C
    Berg, T
    Settmacher, U
    Neuhaus, P
    [J]. HEPATOLOGY, 2001, 33 (05) : 1080 - 1086
  • [25] Kawasaki S, 2002, HEPATO-GASTROENTEROL, V49, P53
  • [26] Koike Y, 2001, CANCER, V91, P561, DOI 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO
  • [27] 2-N
  • [28] Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma:: special reference to imaging diagnosis
    Kumada, T
    Nakano, S
    Takeda, I
    Kiriyama, S
    Sone, Y
    Hayashi, K
    Katoh, H
    Endoh, T
    Sassa, T
    Satomura, S
    [J]. JOURNAL OF HEPATOLOGY, 1999, 30 (01) : 125 - 130
  • [29] Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial
    Lau, WY
    Leung, TWT
    Ho, SKW
    Chan, M
    Machin, D
    Lau, J
    Chan, ATC
    Yeo, W
    Mok, TSK
    Yu, SCH
    Leung, NWY
    Johnson, PJ
    [J]. LANCET, 1999, 353 (9155) : 797 - 801
  • [30] LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473